204 related articles for article (PubMed ID: 30266823)
1. Inhibition of MEK and ATR is effective in a B-cell acute lymphoblastic leukemia model driven by
Chu SH; Song EJ; Chabon JR; Minehart J; Matovina CN; Makofske JL; Frank ES; Ross K; Koche RP; Feng Z; Xu H; Krivtsov A; Nussenzweig A; Armstrong SA
Blood Adv; 2018 Oct; 2(19):2478-2490. PubMed ID: 30266823
[TBL] [Abstract][Full Text] [Related]
2. Instructive Role of MLL-Fusion Proteins Revealed by a Model of t(4;11) Pro-B Acute Lymphoblastic Leukemia.
Lin S; Luo RT; Ptasinska A; Kerry J; Assi SA; Wunderlich M; Imamura T; Kaberlein JJ; Rayes A; Althoff MJ; Anastasi J; O'Brien MM; Meetei AR; Milne TA; Bonifer C; Mulloy JC; Thirman MJ
Cancer Cell; 2016 Nov; 30(5):737-749. PubMed ID: 27846391
[TBL] [Abstract][Full Text] [Related]
3. Activation of Ras-dependent Elk-1 activity by MLL-AF4 family fusion oncoproteins.
Ng MH; Ng RK; Kong CT; Jin DY; Chan LC
Exp Hematol; 2010 Jun; 38(6):481-8. PubMed ID: 20362031
[TBL] [Abstract][Full Text] [Related]
4. The AF4.MLL fusion protein is capable of inducing ALL in mice without requirement of MLL.AF4.
Bursen A; Schwabe K; Rüster B; Henschler R; Ruthardt M; Dingermann T; Marschalek R
Blood; 2010 Apr; 115(17):3570-9. PubMed ID: 20194896
[TBL] [Abstract][Full Text] [Related]
5. Enforced expression of MLL-AF4 fusion in cord blood CD34+ cells enhances the hematopoietic repopulating cell function and clonogenic potential but is not sufficient to initiate leukemia.
Montes R; Ayllón V; Gutierrez-Aranda I; Prat I; Hernández-Lamas MC; Ponce L; Bresolin S; Te Kronnie G; Greaves M; Bueno C; Menendez P
Blood; 2011 May; 117(18):4746-58. PubMed ID: 21389315
[TBL] [Abstract][Full Text] [Related]
6. Frequencies and prognostic impact of RAS mutations in MLL-rearranged acute lymphoblastic leukemia in infants.
Driessen EM; van Roon EH; Spijkers-Hagelstein JA; Schneider P; de Lorenzo P; Valsecchi MG; Pieters R; Stam RW
Haematologica; 2013 Jun; 98(6):937-44. PubMed ID: 23403319
[TBL] [Abstract][Full Text] [Related]
7. Revisiting the biology of infant t(4;11)/MLL-AF4+ B-cell acute lymphoblastic leukemia.
Sanjuan-Pla A; Bueno C; Prieto C; Acha P; Stam RW; Marschalek R; Menéndez P
Blood; 2015 Dec; 126(25):2676-85. PubMed ID: 26463423
[TBL] [Abstract][Full Text] [Related]
8. H3K79 methylation profiles define murine and human MLL-AF4 leukemias.
Krivtsov AV; Feng Z; Lemieux ME; Faber J; Vempati S; Sinha AU; Xia X; Jesneck J; Bracken AP; Silverman LB; Kutok JL; Kung AL; Armstrong SA
Cancer Cell; 2008 Nov; 14(5):355-68. PubMed ID: 18977325
[TBL] [Abstract][Full Text] [Related]
9. High frequency and poor prognosis of late childhood BCR-ABL-positive and MLL-AF4-positive ALL define the need for advanced molecular diagnostics and improved therapeutic strategies in pediatric B-ALL in Pakistan.
Iqbal Z; Akhtar T; Awan T; Aleem A; Sabir N; Rasool M; Absar M; Akram AM; Shammas MA; Shah IH; Khalid M; Taj AS; Jameel A; Alanazi A; Gill AT; Hashmi JA; Hussain A; Sabar MF; Khalid AM; Qazi MH; Karim S; Siddiqi MH; Mahmood A; Iqbal M; Saeed A; Irfan MI
Mol Diagn Ther; 2015 Oct; 19(5):277-87. PubMed ID: 26266519
[TBL] [Abstract][Full Text] [Related]
10. miR-130b and miR-128a are essential lineage-specific codrivers of t(4;11) MLL-AF4 acute leukemia.
Malouf C; Antunes ETB; O'Dwyer M; Jakobczyk H; Sahm F; Landua SL; Anderson RA; Soufi A; Halsey C; Ottersbach K
Blood; 2021 Nov; 138(21):2066-2092. PubMed ID: 34111240
[TBL] [Abstract][Full Text] [Related]
11. Insights into the cellular origin and etiology of the infant pro-B acute lymphoblastic leukemia with MLL-AF4 rearrangement.
Bueno C; Montes R; Catalina P; Rodríguez R; Menendez P
Leukemia; 2011 Mar; 25(3):400-10. PubMed ID: 21135858
[TBL] [Abstract][Full Text] [Related]
12. CDKN1A-mediated responsiveness of MLL-AF4-positive acute lymphoblastic leukemia to Aurora kinase-A inhibitors.
Chen YP; Lin HJ; Chen JS; Tsai MY; Hsieh HP; Chang JY; Chen NF; Chang KC; Huang WT; Su WC; Yang ST; Chang WC; Hung LY; Chen TY
Int J Cancer; 2014 Aug; 135(3):751-62. PubMed ID: 24382688
[TBL] [Abstract][Full Text] [Related]
13. FLT3 activation cooperates with MLL-AF4 fusion protein to abrogate the hematopoietic specification of human ESCs.
Bueno C; Ayllón V; Montes R; Navarro-Montero O; Ramos-Mejia V; Real PJ; Romero-Moya D; Araúzo-Bravo MJ; Menendez P
Blood; 2013 May; 121(19):3867-78, S1-3. PubMed ID: 23479570
[TBL] [Abstract][Full Text] [Related]
14. Unraveling the cellular origin and clinical prognostic markers of infant B-cell acute lymphoblastic leukemia using genome-wide analysis.
Agraz-Doblas A; Bueno C; Bashford-Rogers R; Roy A; Schneider P; Bardini M; Ballerini P; Cazzaniga G; Moreno T; Revilla C; Gut M; Valsecchi MG; Roberts I; Pieters R; De Lorenzo P; Varela I; Menendez P; Stam RW
Haematologica; 2019 Jun; 104(6):1176-1188. PubMed ID: 30679323
[TBL] [Abstract][Full Text] [Related]
15. circRNA circAF4 functions as an oncogene to regulate MLL-AF4 fusion protein expression and inhibit MLL leukemia progression.
Huang W; Fang K; Chen TQ; Zeng ZC; Sun YM; Han C; Sun LY; Chen ZH; Yang QQ; Pan Q; Luo XQ; Wang WT; Chen YQ
J Hematol Oncol; 2019 Oct; 12(1):103. PubMed ID: 31623653
[TBL] [Abstract][Full Text] [Related]
16. AAV8 vector expressing IL24 efficiently suppresses tumor growth mediated by specific mechanisms in MLL/AF4-positive ALL model mice.
Tamai H; Miyake K; Yamaguchi H; Takatori M; Dan K; Inokuchi K; Shimada T
Blood; 2012 Jan; 119(1):64-71. PubMed ID: 22025528
[TBL] [Abstract][Full Text] [Related]
17. Targeting MLL-AF4 with short interfering RNAs inhibits clonogenicity and engraftment of t(4;11)-positive human leukemic cells.
Thomas M; Gessner A; Vornlocher HP; Hadwiger P; Greil J; Heidenreich O
Blood; 2005 Nov; 106(10):3559-66. PubMed ID: 16046533
[TBL] [Abstract][Full Text] [Related]
18. MEK inhibition is a promising therapeutic strategy for MLL-rearranged infant acute lymphoblastic leukemia patients carrying RAS mutations.
Kerstjens M; Driessen EM; Willekes M; Pinhanços SS; Schneider P; Pieters R; Stam RW
Oncotarget; 2017 Feb; 8(9):14835-14846. PubMed ID: 27588400
[TBL] [Abstract][Full Text] [Related]
19. The silent mutational landscape of infant MLL-AF4 pro-B acute lymphoblastic leukemia.
Dobbins SE; Sherborne AL; Ma YP; Bardini M; Biondi A; Cazzaniga G; Lloyd A; Chubb D; Greaves MF; Houlston RS
Genes Chromosomes Cancer; 2013 Oct; 52(10):954-60. PubMed ID: 23893660
[TBL] [Abstract][Full Text] [Related]
20. Mll-AF4 Confers Enhanced Self-Renewal and Lymphoid Potential during a Restricted Window in Development.
Barrett NA; Malouf C; Kapeni C; Bacon WA; Giotopoulos G; Jacobsen SEW; Huntly BJ; Ottersbach K
Cell Rep; 2016 Jul; 16(4):1039-1054. PubMed ID: 27396339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
